Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene - PubMed
Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene
Jana Kralovicova et al. Nucleic Acid Ther. 2016 Dec.
Abstract
ATM (ataxia-telangiectasia, mutated) is an important cancer susceptibility gene that encodes a key apical kinase in the DNA damage response pathway. ATM mutations in the germ line result in ataxia-telangiectasia (A-T), a rare genetic syndrome associated with hypersensitivity to double-strand DNA breaks and predisposition to lymphoid malignancies. ATM expression is limited by a tightly regulated nonsense-mediated RNA decay (NMD) switch exon (termed NSE) located in intron 28. In this study, we identify antisense oligonucleotides that modulate NSE inclusion in mature transcripts by systematically targeting the entire 3.1-kb-long intron. Their identification was assisted by a segmental deletion analysis of transposed elements, revealing NSE repression upon removal of a distant antisense Alu and NSE activation upon elimination of a long terminal repeat transposon MER51A. Efficient NSE repression was achieved by delivering optimized splice-switching oligonucleotides to embryonic and lymphoblastoid cells using chitosan-based nanoparticles. Together, these results provide a basis for possible sequence-specific radiosensitization of cancer cells, highlight the power of intronic antisense oligonucleotides to modify gene expression, and demonstrate transposon-mediated regulation of NSEs.
Keywords: ATM; alternative splicing; antisense oligonucleotides; lymphoid cancer; nanoparticles; nonsense-mediated RNA decay; transposon.
Conflict of interest statement
Author Disclosure Statement A part of this work is subject to a UK patent application by the University of Southampton.
Figures

Identification of transposed elements in ATM intron 28 that influence NSE activation. (A) Location of transposed elements in intron 28 and schematics of NSE activation. Canonical exons [54] are shown as gray boxes, the NSE as a white box, introns flanking the NSE as horizontal lines, and their splicing by dotted lines. Deletions (numbered 1–6) of transposed elements are shown as horizontal white rectangles; UC, a unique sequence lacking recognizable transposons. Deletion numbers correspond to lanes in (B). RT-PCR primers are denoted by black arrows. A scale is at the top. The NSE sequence is boxed in the lower panel. Asterisk denotes the C/T variant rs609261 located at the NSE 3′ss; rs4988000 (not shown) is 64 bp downstream of the NSE 5′ss. (B) Deletion of antisense Alu and MER51 alters NSE inclusion levels. WT and mutated constructs [designated 1–6 in (A)] were transiently transfected into HEK293 cells (mock) depleted of U2AF35. NSE+/−, RNA products with/without NSE. Columns represent mean NSE inclusion (%), error bars are SDs of two independent transfection experiments. Asterisks denote P values <0.01 for comparisons with the WT. 5′ss, 5′ splice site; ATM, ataxia-telangiectasia, mutated; NSE, NMD switch exon; RT-PCR, reverse transcription polymerase chain reaction; SDs, standard deviations; WT, wild-type.

Identification of intronic SSOs that activate or repress NSE. (A) Location of tested SSOs in intron 28 relative to transposed elements (for legend, see Fig. 1A). The branch point sequence (GGCTG
AT; branch point adenosine is underlined) of NSE is denoted by a vertical arrowhead. (B) Intronic SSOs that alter NSE inclusion in exogenous transcripts. SSOs are at the bottom. Multiple controls are boxed. SSO sequences are in Table 2. The average NSE inclusion in controls is denoted by a dotted line, error bars are SDs of two independent transfection experiments. Columns represent mean NSE inclusion levels, asterisks show significant P values. (C) SSOs targeting single-stranded regions tended to repress endogenous NSE. r, Pearson correlation coefficient. The P value is in brackets. SSOs, splice-switching oligonucleotides.

TMC-SA-assisted delivery of SSO-NSE3 to human cell lines leads to NSE repression. (A) NSE inclusion in HEK293 cells is inhibited upon exposure of SSO-NSE3/TMC-SA nanocomplexes. Sc, a scrambled control with the same modification. M, size marker. Error bars denote SDs of two transfection experiments. P values are shown at the top for the indicated comparisons. (B) NSE repression in VAVY cells exposed to the SSO-NSE3/TMC-SA nanocomplexes. TMC-SA, stearylated trimethylated chitosan.

Inverted repeats in the MER51 element of ATM intron 28. The alignment was carried out by RepeatMasker [35]. v, transversions; i, transitions. Putative purine-rich loops (highlighted in gray) are flanked by inverted repeats (underlined) that may form stable base-pairing interactions during transcription. The long terminal repeat homology region originally described for the MER51 family [49] is in italics. The aligned segment corresponds to deletion 4 shown in Fig. 1A. The MER51A consensus sequence is in the antisense orientation.
Similar articles
-
Kralovicova J, Knut M, Cross NC, Vorechovsky I. Kralovicova J, et al. Sci Rep. 2016 Jan 6;6:18741. doi: 10.1038/srep18741. Sci Rep. 2016. PMID: 26732650 Free PMC article.
-
Exploring Splicing-Switching Molecules For Seckel Syndrome Therapy.
Scalet D, Balestra D, Rohban S, Bovolenta M, Perrone D, Bernardi F, Campaner S, Pinotti M. Scalet D, et al. Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):15-20. doi: 10.1016/j.bbadis.2016.09.011. Epub 2016 Sep 14. Biochim Biophys Acta Mol Basis Dis. 2017. PMID: 27639833
-
Pastor T, Talotti G, Lewandowska MA, Pagani F. Pastor T, et al. Nucleic Acids Res. 2009 Nov;37(21):7258-67. doi: 10.1093/nar/gkp778. Nucleic Acids Res. 2009. PMID: 19773425 Free PMC article.
-
Exonization of transposed elements: A challenge and opportunity for evolution.
Schmitz J, Brosius J. Schmitz J, et al. Biochimie. 2011 Nov;93(11):1928-34. doi: 10.1016/j.biochi.2011.07.014. Epub 2011 Jul 26. Biochimie. 2011. PMID: 21787833 Review.
-
Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y, Yokota T. Echigoya Y, et al. Nucleic Acid Ther. 2014 Feb;24(1):57-68. doi: 10.1089/nat.2013.0451. Epub 2013 Dec 31. Nucleic Acid Ther. 2014. PMID: 24380394 Review.
Cited by
-
RNA splicing dysregulation and the hallmarks of cancer.
Bradley RK, Anczuków O. Bradley RK, et al. Nat Rev Cancer. 2023 Mar;23(3):135-155. doi: 10.1038/s41568-022-00541-7. Epub 2023 Jan 10. Nat Rev Cancer. 2023. PMID: 36627445 Free PMC article. Review.
-
Roles of Transposable Elements in the Different Layers of Gene Expression Regulation.
Drongitis D, Aniello F, Fucci L, Donizetti A. Drongitis D, et al. Int J Mol Sci. 2019 Nov 15;20(22):5755. doi: 10.3390/ijms20225755. Int J Mol Sci. 2019. PMID: 31731828 Free PMC article. Review.
-
Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.
Lin JC. Lin JC. Int J Mol Sci. 2017 Dec 28;19(1):75. doi: 10.3390/ijms19010075. Int J Mol Sci. 2017. PMID: 29283381 Free PMC article. Review.
-
Function, clinical application, and strategies of Pre-mRNA splicing in cancer.
Di C, Syafrizayanti, Zhang Q, Chen Y, Wang Y, Zhang X, Liu Y, Sun C, Zhang H, Hoheisel JD. Di C, et al. Cell Death Differ. 2019 Jul;26(7):1181-1194. doi: 10.1038/s41418-018-0231-3. Epub 2018 Nov 21. Cell Death Differ. 2019. PMID: 30464224 Free PMC article. Review.
-
Targeting Splicing in the Treatment of Human Disease.
Suñé-Pou M, Prieto-Sánchez S, Boyero-Corral S, Moreno-Castro C, El Yousfi Y, Suñé-Negre JM, Hernández-Munain C, Suñé C. Suñé-Pou M, et al. Genes (Basel). 2017 Feb 24;8(3):87. doi: 10.3390/genes8030087. Genes (Basel). 2017. PMID: 28245575 Free PMC article. Review.
References
-
- Wahl MC, Will CL. and Luhrmann R. (2009). The spliceosome: design principles of a dynamic RNP machine. Cell 136:701–718 - PubMed
-
- Le Hir H, Nott A. and Moore MJ. (2003). How introns influence and enhance eukaryotic gene expression. Trends Biochem Sci 28:215–220 - PubMed
-
- Lev-Maor G, Sorek R, Shomron N. and Ast G. (2003). The birth of an alternatively spliced exon: 3′ splice-site selection in Alu exons. Science 300:1288–1291 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous